Oliver Lagore Vanvalin Investment Group’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Oliver Lagore Vanvalin Investment Group’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-47	Closed	-$5.04K	–	856
2023 Q1	$5.04K	Buy	47 +6	+15%	+$691	﹤0.01%	481
2022 Q4	$4.51K	Buy	+41	New	+$2.66K	﹤0.01%	477

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Oliver Lagore Vanvalin Investment Group's RXDX Position: Q2 2023 in Review

Oliver Lagore Vanvalin Investment Group sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 47 shares — an estimated $5.04K sold.

Oliver Lagore Vanvalin Investment Group first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $5.04K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Oliver Lagore Vanvalin Investment Group reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Oliver Lagore Vanvalin Investment Group sold 47 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $5.04K.
Oliver Lagore Vanvalin Investment Group first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Oliver Lagore Vanvalin Investment Group's Prometheus Biosciences, Inc. Common Stock position peaked at $5.04K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Oliver Lagore Vanvalin Investment Group's 13F filing for Q2 2023, filed 8 Aug 2023.